# Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

> **NCT01174732** · PHASE2 · COMPLETED · sponsor: **Amphastar Pharmaceuticals, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Asthma
- Bronchospasm

## Interventions

- **DRUG:** albuterol inhalation powder
- **DRUG:** albuterol inhalation powder
- **DRUG:** albuterol inhalation powder
- **DRUG:** albuterol inhalation powder
- **DRUG:** Placebo
- **DRUG:** albuterol inhalation aerosol
- **DRUG:** albuterol inhalation aerosol

## Key facts

- **NCT ID:** NCT01174732
- **Lead sponsor:** Amphastar Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-10
- **Final completion:** 2011-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01174732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01174732, "Dose-Ranging Study of A006 DPI, in Adult Asthma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01174732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*